The opening salvo in what promises to be one of the hottest debates in the new Congress was fired January 29 during a day-long hearing in the House Committee on Oversight and Reform—how to lower the price of prescription drugs. And it didn’t take long to make it clear that patents are right in the middle of the scrum. The role of patents was a prominent part of the House hearing. While cursory nods were made to the importance of encouraging innovation, the witnesses discussed how patent exclusivity, thickets, and evergreening drove up prices while promoting the greater use of Patent Trial and Appeal Board (PTAB) reviews against drug patents. The Committee was assured that curtailing patents wouldn’t harm innovation because the National Institutes of Health (NIH) is such an important funder of life science R&D.
The post Patents in the Crosshairs During House Drug Pricing Debate appeared first on IPWatchdog.com | Patents & Patent Law.
Business
- Tech Companies Should Strongly Consider Monetizing Their Patent Portfolios During the Economic Downturn
- (Not) Copyright Infringement: Is dbrand Infringing Nintendo’s IP?
- The Transmissibility of Information: How Your Trade Secrets Are Like a Virus
- Examining Antitrust Guidance on Cooperation in Fighting COVID-19
- Everything Depends on Coronavirus R&D Partnerships—Don’t Let the Critics Wreck Them
Recent Posts
- ‘Unalienable Rights’: Understanding America’s Growing Disdain for Physical and Intangible Property
- This Week in Washington IP: Algorithmic Biases in AI, Federal Funding of R&D Programs and Digitalization-Driven Improvements to Energy Efficiency
- Supreme Court’s Booking.com Ruling Signals Uptick in Registration of ‘Generic.com’ Marks
- Sixth Annual Firecracker 25: My Best Songs of All Time
- Other Barks & Bites for Friday, July 3: Busy Week for USPTO Announcements, New Vision Gaming Says PTAB Institution Process is Unconstitutional, Federal Circuit Affirms Invalidity of Enbrel Patent Claims